C.Q. Pharmaceutical Holding: Announcement on the completion of the implementation of the plan for the company's chairman to increase shareholding and the results of the shareholding increase.
C.Q. Pharmaceutical Holding: Simplified Equity Change Report
C.Q. Pharmaceutical Holding: 2023 dividend payment implementation announcement
C.Q. Pharmaceutical Holding: Shareholder dividend return plan for the next three years (2024-2026)
C.Q. Pharmaceutical Holding: Announcement on the 2023 Profit Distribution Plan
Heavy Pharmaceutical Holdings: Announcement on the Chairman\'s Plan to Increase Shares in the Company
Heavy Pharmaceutical Holdings: Announcement on the increase in the company\'s shares held by the Chief Financial Officer and Secretary of the Board of Directors
Heavy Medicine Holdings: Announcement on the Chairman\'s increase in the company\'s shares
Heavy Pharmaceutical Holdings: Announcement on the completion of the implementation of the plan to reduce the holdings of shareholders holding 5% or more of the original shares
Heavy Pharmaceutical Holdings: Announcement on the release of the pledge of shares held by shareholders who originally held 5% or more of the shares
Heavy Pharmaceutical Holdings: Announcement on the planned reduction of shareholding by more than 5% of shareholders over half of the time
Heavy Pharmaceutical Holdings: 2022 Annual Equity Distribution Implementation Notice
Heavy Pharmaceutical Holdings: Legal opinion of Beijing Zhonglun (Chengdu) Law Firm on the termination of the 2020 Restricted Stock Incentive Plan and the implementation of the repurchase and cancellation of restricted stocks by Heavy Pharmaceutical Holdin
Heavy Pharmaceutical Holdings: Announcement on the Cancellation of Restricted Stock Repurchase in 2020
Heavy Pharmaceutical Holdings: Announcement on shareholders\' share holdings of 5% or more originally planned to reduce their holdings by more than half
Heavy Pharmaceutical Holdings: Simplified Report on Changes in Equity
Heavy Pharmaceutical Holdings: Announcement on shareholders holding 5% or more of their shares to reduce their holdings by 1%
Heavy Pharmaceutical Holdings: Pre-disclosure announcement on plans to reduce holdings for shareholders holding 5% or more of the shares
Heavy Pharmaceutical Holdings: Announcement on 2022 Profit Distribution Plan
Heavy Pharmaceutical Holdings: Notice to Creditors on Repurchase and Cancellation of Restricted Shares
No Data